4D Molecular Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $56.9 million, compared to a net loss of $43.8 million for the same period in 2024. For the nine months ended September 30, 2025, the company recorded a net loss of $159.5 million, up from $111.2 million in the prior year. The increase in losses is attributed to higher operating expenses, particularly in research and development, which rose by 28% to $49.4 million for the quarter and by 41% to $138.1 million for the nine-month period. The company generated $90,000 in collaboration and license revenue for the third quarter, a significant increase from $3,000 in the same quarter last year, and $119,000 for the nine months, compared to $36,000 in 2024.
The company's total operating expenses for the third quarter were $61.3 million, a 20% increase from $51.1 million in the prior year. This rise was primarily driven by increased clinical trial costs associated with the development of its lead product candidates, 4D-150 and 4D-710. The company also reported a decrease in general and administrative expenses, which fell by 6% to $11.8 million for the quarter, reflecting a reduction in headcount. As of September 30, 2025, 4D Molecular Therapeutics had cash, cash equivalents, and marketable securities totaling $372.2 million, down from $560.4 million at the end of 2024.
In terms of strategic developments, 4D Molecular Therapeutics has made significant progress in its clinical trials. The company announced that enrollment in its Phase 3 clinical trial for 4D-150, aimed at treating wet age-related macular degeneration (AMD), exceeded initial projections, with over 200 patients enrolled. Additionally, the company entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd., granting Otsuka exclusive rights to develop and commercialize 4D-150 in several Asia-Pacific markets. This agreement includes an upfront cash payment of $85 million and potential milestone payments totaling up to $335.5 million.
Operationally, the company has undergone a workforce reduction of approximately 25% to streamline operations and focus on its key product candidates. This restructuring is expected to yield annual cash savings of about $15 million. The company continues to prioritize the development of 4D-150 and 4D-710, with plans to seek additional funding to support ongoing clinical trials and operational needs. Despite the current financial challenges, management believes that existing cash reserves will sustain operations for at least the next year, although they acknowledge the need for further capital to support future growth and development initiatives.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company specializing in innovative genetic medicines for ophthalmology and pulmonology. Its lead product, 4D-150, targets retinal diseases like wet AMD and diabetic macular edema, while 4D-710 aims to treat cystic fibrosis. Utilizing its proprietary Therapeutic Vector Evolution platform, the company addresses significant unmet medical needs, focusing on durable therapies with reduced treatment burdens. 4DMT is positioned for impactful advancements in patient care.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.